A trial to study of treatment with a new PPI for infection of H. pylori with Clarithromycin resistance

A trial to study of treatment with a new PPI for infection of H. pylori with Clarithromycin resistance - A trial to study of treatment with a new PPI for infection of H. pylori with Clarithromycin resistance

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018595

Enrollment

100

Registered

2015-08-07

Start date

2015-08-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic gastritis infected by H. pylori with Clarithromycin resistance

Interventions

Rabeprazole 10mg, Amoxicillin 750mg and Metronidazole 250mg bid(bis in die), for 1 week. Vonoprazan 20mg, Amoxicillin 750mg and Metronidazole 250mg bid(bis in die), for 1 week. Vonoprazan 20mg, Amox

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients of chronic gastritis infected by H. pylori with Clarithromycin resistance, who want to eradicate HP.

Exclusion criteria

Exclusion criteria: Patients who could not agree with this trial.

Design outcomes

Primary

Measure	Time frame
Eradication rate Urease Breath Test(UBT) will be performed at six to twelve weeks after HP eradication.	—

Countries

Japan

Contacts

Public ContactChiaki KUSUMOTO

Nippon Kokan Fukuyama Hospital Dep. of Gastroenterology

chiaki_kusumoto@nkfh.or.jp084-945-3106

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026